Sygnature Discovery, is the UK’s largest independent provider of integrated drug discovery resource and expertise to pharmaceutical companies, biotechs and academic groups worldwide. The company provides advanced research into new medicines to treat a range of debilitating diseases and employs over 200 laboratory-based, industry-experienced PhD medicinal chemists, computational chemists, in vitro biologists, in vivo pharmacologists and DMPK scientists.
Sygnature adds significant value to collaborations by providing advanced scientific knowledge and intellectual input to accelerate clients’ drug discovery projects from hit through to pre-clinical candidate. We have an enviable track record of success for our clients. Sygnature scientists are named inventors on numerous patents, 27 drug candidates are in pre-clinical development, with 14 currently undergoing clinical trials in patients (Phases I and II).